Expression of human paraoxonase (PON1) during development

被引:92
作者
Cole, TB
Jampsa, RL
Walter, BJ
Arndt, TL
Richter, RJ
Shih, DM
Tward, A
Lusis, AJ
Jack, RM
Costa, LG
Furlong, CE
机构
[1] Univ Washington, Div Med Genet, Dept Environm Hlth, Seattle, WA 98195 USA
[2] Univ Washington, Div Med Genet, Dept Med, Seattle, WA 98195 USA
[3] Univ Washington, Div Med Genet, Dept Genome Sci, Seattle, WA 98195 USA
[4] Univ Calif Los Angeles, Sch Med, Dept Mol Genet & Microbiol, Los Angeles, CA USA
[5] Univ Calif Los Angeles, Sch Med, Div Cardiol, Dept Med, Los Angeles, CA USA
[6] Childrens Hosp, Seattle, WA USA
[7] Reg Med Ctr, Seattle, WA USA
来源
PHARMACOGENETICS | 2003年 / 13卷 / 06期
关键词
PON1; paraoxonase; developmental; regulation; gene expression; transgenic mice; organophosphorus insecticides;
D O I
10.1097/00008571-200306000-00007
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background Paraoxonase (PON1), a HDL-associated enzyme, protects against toxicity from specific organophosphorus compounds and oxidized lipids. Common polymorphisms in the PON1 gene have been identified and characterized in the coding region, 5' regulatory region and 3' UTR. The Q192R coding region polymorphism determines substrate-dependent differences in catalytic efficiency of hydrolysis. The -108CT polymorphism in the 5' regulatory region has a significant effect on PON1 expression, with the -108C allele expressing on average twice the level of plasma PON1 as the -108T allele. In addition to the effects of regulatory and coding region polymorphisms on PON1 levels and activity, plasma PON1 levels are also developmentally regulated. Since PON1 levels are important in determining resistance to specific organophosphorus compounds, the time course of appearance of PON1 in newborns is of great interest. Results We report here that PON1 levels plateau between 6 to 15 months of age, and that variability in the age at which PON1 levels plateau is quite variable among individuals. In mice and rats, plasma PON1 activity reaches a plateau at 3 weeks of age. In mice that lack endogenous PON1, human transgenes encoding either PON1(Q192) or PON1(R192) under the control of the human PON1 regulatory sequences exhibited a similar time course of expression as that seen in wild-type mice, indicating conservation of the developmental regulatory elements between mouse and human PON1. (C) 2003 Lippincott Williams Wilkins.
引用
收藏
页码:357 / 364
页数:8
相关论文
共 65 条
  • [11] Analysis of paraoxonase (PON1) L55M status requires both genotype and phenotype
    Brophy, VH
    Jarvik, GP
    Richter, RJ
    Rozek, LS
    Schellenberg, GD
    Furlong, CE
    [J]. PHARMACOGENETICS, 2000, 10 (05): : 453 - 460
  • [12] Effects of 5′ regulatory-region polymorphisms on paraoxonase-gene (PON1) expression
    Brophy, VH
    Jampsa, RL
    Clendenning, JB
    McKinstry, LA
    Jarvik, GP
    Furlong, CE
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2001, 68 (06) : 1428 - 1436
  • [13] Polymorphisms in the human paraoxonase (PON1) promoter
    Brophy, VH
    Hastings, MD
    Clendenning, JB
    Richter, RJ
    Jarvik, GP
    Furlong, CE
    [J]. PHARMACOGENETICS, 2001, 11 (01): : 77 - 84
  • [14] Brophy VH, 2002, PARAOXONASE PON1 HLT, P53
  • [15] ROLE OF DETOXICATION PATHWAYS IN ACUTE TOXICITY LEVELS OF PHOSPHOROTHIONATE INSECTICIDES IN THE RAT
    CHAMBERS, JE
    MA, TG
    BOONE, JS
    CHAMBERS, HW
    [J]. LIFE SCIENCES, 1994, 54 (18) : 1357 - 1364
  • [16] COSTA LG, 2002, PARAOXONASE PON1 HLT, P165
  • [17] The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin
    Davies, HG
    Richter, RJ
    Keifer, M
    Broomfield, CA
    Sowalla, J
    Furlong, CE
    [J]. NATURE GENETICS, 1996, 14 (03) : 334 - 336
  • [18] Paraoxonase and atherosclerosis
    Durrington, PN
    Mackness, B
    Mackness, MI
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (04) : 473 - 480
  • [19] ECKERSON HW, 1983, AM J HUM GENET, V35, P1126
  • [20] ECOBICHON DJ, 1973, CLIN PHARMACOL THER, V14, P41